SEQUENTIAL ANTITHYMOCYTE GLOBULIN & AMIFOSTINE FOR MDS

序贯抗胸腺细胞球蛋白

• 批准号: 6265603
• 负责人: JEANNE E ANDERSON
• 金额: $ 1.64万
• 依托单位: UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6265603
• 关键词: acute myelogenous leukemia; antileukemic agent; blood disorder chemotherapy; clinical research; clinical trials; combination chemotherapy; drug interactions; dyserythropoietic anemia; human subject; human therapy evaluation; pathologic process

The myelodysplastic syndrome is a heterogeneous group of clonal hematopoietic disorders characterized by ineffective hematopoiesis, progressive peripheral cytopenias, and a tendency to progress to acute myeloid leukemia. New therapeutic options in MDS which are still under investigation include amifostine and antithymocite globulin (ATG). Although both amifostine and ATG have shown effects as individual agents in improving cytopenias and, perhaps, marrow blast count, there have been many patients treated with these agents who had none or minimal response in one or more cell lines. The cause of cytopenias and progression to AML is likely multifactorial. This study hypothesizes that treatment with the combination of the two agents -- each of which has a different mechanism of action -- may be synergistic in improving peripheral counts and reducing disease progression.

骨髓增生异常综合征是一组异质性克隆性造血疾病，其特征是无效造血、进行性外周血细胞减少以及进展为急性髓系白血病的倾向。 仍在研究中的 MDS 的新治疗选择包括氨磷汀和抗胸腺素球蛋白 (ATG)。尽管氨磷汀和 ATG 作为单独的药物都显示出改善血细胞减少症以及骨髓母细胞计数的效果，但许多接受这些药物治疗的患者在一种或多种细胞系中没有或只有很少的反应。 血细胞减少和进展为 AML 的原因可能是多因素的。 这项研究假设，两种药物的联合治疗（每种药物都有不同的作用机制）可能在改善外周细胞计数和减少疾病进展方面具有协同作用。